Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

2.

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2010 Mar;67(3):308-16. doi: 10.1002/ana.21953.

3.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

4.

Serial MRI and CSF biomarkers in normal aging, MCI, and AD.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 13;75(2):143-51. doi: 10.1212/WNL.0b013e3181e7ca82.

5.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

6.

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

AJNR Am J Neuroradiol. 2013 Mar;34(3):505-10. doi: 10.3174/ajnr.A3267. Epub 2012 Sep 13.

7.

Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.

Weise D, Tiepolt S, Awissus C, Hoffmann KT, Lobsien D, Kaiser T, Barthel H, Sabri O, Gertz HJ.

J Alzheimers Dis. 2015;48(2):425-32. doi: 10.3233/JAD-150229.

PMID:
26402006
8.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

9.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

10.

Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.

Schroeter ML, Tiepolt S, Marschhauser A, Thöne-Otto A, Hoffmann KT, Barthel H, Obrig H, Sabri O.

BMC Neurol. 2015 Aug 26;15:152. doi: 10.1186/s12883-015-0410-5.

11.

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):287-93. doi: 10.1212/WNL.0b013e3181af79e5.

12.
13.

Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH.

Brain. 2013 May;136(Pt 5):1383-98. doi: 10.1093/brain/awt062. Epub 2013 Apr 9.

14.

The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11.

15.

Biomarker modeling of Alzheimer's disease.

Jack CR Jr, Holtzman DM.

Neuron. 2013 Dec 18;80(6):1347-58. doi: 10.1016/j.neuron.2013.12.003. Review.

16.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

17.

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.

Small SA, Duff K.

Neuron. 2008 Nov 26;60(4):534-42. doi: 10.1016/j.neuron.2008.11.007. Review.

18.

[Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians].

Trombella S, Assal F, Zekry D, Gold G, Giannakopoulos P, Garibotto V, Démonet JF, Frisoni GB.

Rev Med Suisse. 2016 Apr 20;12(515):795-8. Review. French.

PMID:
27276723
19.

Comparing predictors of conversion and decline in mild cognitive impairment.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 20;75(3):230-8. doi: 10.1212/WNL.0b013e3181e8e8b8. Epub 2010 Jun 30.

20.

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, Vemuri P, Mielke MM, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC.

Lancet Neurol. 2017 Jun;16(6):435-444. doi: 10.1016/S1474-4422(17)30077-7. Epub 2017 Apr 26.

PMID:
28456479

Supplemental Content

Support Center